Technology news and Jobs 
Science Dogs wagging tails over approval of their first cancer medicine
Science Dogs wagging tails over approval of their first cancer medicine | Dogs wagging tails over approval of their first cancer medicine |
|
| by William Atkins | |
| Monday, 08 June 2009 | |
|
Page 1 of 2   
Featured Whitepaper
5 Best Practices for Smartphone Support
Science DiscussionsPfizer Animal Health makes Palladia, the anti-cancer drug that was developed especially for our dogs. It was announced on Thursday, June 3, 2009, by the Food and Drug Administration (FDA) that the branded product Palladia (or PALLADIA, scientific name “toceranib phosphate”) would be approved for the treatment of mast cell tumors (MCTs). Dr. Lawrence McGill, a veterinary pathologist at ARUP Laboratories (Salt Lake City, Utah) is quoted in ABCNews.com. Dr. McGill says, "It is a real breakthrough for a cancer drug to be made specifically for animals. Hopefully, this is the start of many products coming forward so that we can help pets with cancer." Dr. McGill adds, "I strongly suspect that veterinary medicine will continue to utilize human anti-cancer drugs where appropriate, but new drugs directed towards improving the health and welfare of dogs, cats and other pets will be greatly utilized and appreciated.” The type of cancer treated by Palladia is canine cutaneous mast cell tumors. Mast cell tumors are found in about one out of four of the skin tumors of older dogs and cats. Also called mastocytoma, the mast cell tumors originates in bone marrow and found frequently in the connective tissues of the body. As a normal component of the immune system, these mast cells release histamine during allergic reactions. For more information on Palladia and MCT, please read page two. |
| < Next story in category | Previous story in the category > |
|---|
